Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:45 PM
Ignite Modification Date:
2025-12-24 @ 11:45 PM
NCT ID:
NCT04177251
Eligibility Criteria:
For IPF patients:
Inclusion Criteria:
* diagnosis of idiopathic pulmonary fibrosis according to the 2011 ATS / ERS guidelines with Multidisciplinary discussion;
* informed consent signed and obtained before study enrollment.
Exclusion Criteria:
* having already received (currently or in the past) therapy with pirfenidone or nintedanib;
* participation in other experimental interventional protocols with medicinal use;
* need for oxygen therapy at rest;
* active smoking;
* presence of atrial fibrillation or atrial flutter;
* amputation of a limb or severe peripheral vasculopathy (defined as the presence of previous stenting or vascular surgery of the lower limbs or as the presence of claudication with onset of symptoms for intervals \<700 m).
For healthy volunteers:
Inclusion Criteria:
\- informed consent signed and obtained before study enrollment.
Exclusion Criteria:
* active smoking;
* presence of atrial fibrillation or atrial flutter;
* amputation of a limb or severe peripheral vasculopathy (defined as the presence of previous stenting or vascular surgery of the lower limbs or as the presence of claudication with onset of symptoms for intervals \<700 m);
* diagnostic suspicion of IPF at baseline (T1);
* participation in other experimental protocols.
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
40 Years
Study:
NCT04177251
Study Brief:
Protocol Section:
NCT04177251